ADMA Biologics Inc $ADMA Stock Holdings Lessened by Aberdeen Group plc

Aberdeen Group plc trimmed its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 13.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 963,949 shares of the biotechnology company’s stock after selling 152,363 shares during the quarter. Aberdeen Group plc owned 0.41% of ADMA Biologics worth $17,582,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in ADMA. Salomon & Ludwin LLC bought a new position in ADMA Biologics during the third quarter valued at approximately $25,000. Rothschild Investment LLC raised its position in ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,495 shares in the last quarter. Clearstead Advisors LLC raised its position in ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 795 shares in the last quarter. iSAM Funds UK Ltd bought a new position in ADMA Biologics during the third quarter valued at approximately $34,000. Finally, RiverPark Advisors LLC bought a new position in ADMA Biologics during the third quarter valued at approximately $35,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ADMA shares. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $9.28 on Tuesday. The firm has a market cap of $2.21 billion, a P/E ratio of 15.47 and a beta of 0.82. The firm’s 50-day simple moving average is $14.63 and its 200-day simple moving average is $16.14. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. The firm had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.46 earnings per share. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the transaction, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.